Skip to Main Content

Author Details

E Alejandro Sweet-Cordero
University of California San Francisco
1989
81
35
Nathan Sheffield (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37400538Discovery of VH domains that allosterically inhibit ENPP1.Nat Chem Biol2024
37703185Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.Clin Cancer Res2024
37400538Discovery of VH domains that allosterically inhibit ENPP1.Nat Chem Biol2024
37703185Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach.Clin Cancer Res2024
36711882Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities.bioRxiv2023
37933765Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.Cancer Rep (Hoboken)2023
36711882Development and characterization of new patient-derived xenograft (PDX) models of osteosarcoma with distinct metastatic capacities.bioRxiv2023
37205599FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer.bioRxiv2023
37398210FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.Res Sq2023
37001527Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.Cancer Cell2023
37933765Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patients.Cancer Rep (Hoboken)2023
37205599FET fusion oncoproteins disrupt physiologic DNA repair networks in cancer.bioRxiv2023
37001527Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.Cancer Cell2023
37398210FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.Res Sq2023
35321431APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.Front Oncol2022
35594991Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine Stimulation.Mol Cell Proteomics2022
35767377A 3D Osteosarcoma Model with Bone-Mimicking Cues Reveals a Critical Role of Bone Mineral and Informs Drug Discovery.Adv Healthc Mater2022
36008377Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.Nat Commun2022
35740503Synthetic Vulnerabilities in the KRAS Pathway.Cancers (Basel)2022
35927023Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy.Cold Spring Harb Mol Case Stud2022
36316687Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies.Genome Med2022
35321431APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.Front Oncol2022
35740503Synthetic Vulnerabilities in the KRAS Pathway.Cancers (Basel)2022
35767377A 3D Osteosarcoma Model with Bone-Mimicking Cues Reveals a Critical Role of Bone Mineral and Informs Drug Discovery.Adv Healthc Mater2022
35594991Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine Stimulation.Mol Cell Proteomics2022
35927023Detection of a GLIS3 fusion in an infant with AML refractory to chemotherapy.Cold Spring Harb Mol Case Stud2022
36008377Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.Nat Commun2022
36316687Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies.Genome Med2022
32815876NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.J Pediatr Hematol Oncol2021
34353895A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.Mol Cancer Ther2021
32929263Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses.Nat Biotechnol2021
32815876NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML.J Pediatr Hematol Oncol2021
34944883Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.Cancers (Basel)2021
34944883Comparison of the Transcriptomic Signatures in Pediatric and Adult CML.Cancers (Basel)2021
34353895A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.Mol Cancer Ther2021
32929263Oncoprotein-specific molecular interaction maps (SigMaps) for cancer network analyses.Nat Biotechnol2021
31511612Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.Leukemia2020
32238925CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities.Nature2020
31874105The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.J Clin Invest2020
32767231Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies.Adv Exp Med Biol2020
33139339An Expanded Tool Kit for Modeling the Oncogenic Functions of KRAS.Cancer Discov2020
32522868Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand.Proc Natl Acad Sci U S A2020
33283136Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature.JCO Precis Oncol2020
32727735Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities.Cancer Discov2020
33049203Advances and Challenges in Pediatric and Childhood Cancers.Cancer Cell2020
31511612Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.Leukemia2020
31874105The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas.J Clin Invest2020
33283136Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature.JCO Precis Oncol2020
33139339An Expanded Tool Kit for Modeling the Oncogenic Functions of KRAS.Cancer Discov2020
33049203Advances and Challenges in Pediatric and Childhood Cancers.Cancer Cell2020
  • 1 - 50 of 162

Recommended Authors

University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 2
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 7
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 22
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 7
Broad Institute of Harvard and MIT
Career Start Year 2004
Number of shared co-authors 15
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 10
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 8
Amsterdam University Medical Centers location AMC
Career Start Year 1999
Number of shared co-authors 17
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 7
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 5
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 9
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 3
University of California San Francisco
Career Start Year 1993
Number of shared co-authors 6
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 8
St Jude Children's Research Hospital
Career Start Year 1991
Number of shared co-authors 15
University of Minnesota
Career Start Year 1990
Number of shared co-authors 16
Broad Institute of Harvard and MIT
Career Start Year 1990
Number of shared co-authors 12
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 6
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 7
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 12
University of California san francisco
Career Start Year 1985
Number of shared co-authors 23
Dana-Farber Cancer Institute
Career Start Year 1984
Number of shared co-authors 19
Broad Institute
Career Start Year 1983
Number of shared co-authors 31
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 3
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 14
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 12

Collaborators

Co-authored papers 17
Co-authored papers 9
University of California San Francisco
Co-authored papers 5
Co-authored papers 5
Co-authored papers 5
Stanford University School of Medicine
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Department of Pediatrics Stanford University Stanford California USA.
Co-authored papers 4
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 3
Center for Cancer Research, National Cancer Institute
Co-authored papers 3
Genomics Institute, University of California Santa Cruz
Co-authored papers 3
UC Santa Cruz Genomics Institute
Co-authored papers 3
Broad Institute of MIT and Harvard
Co-authored papers 3
Stanford University School of Medicine, Center for Clinical Sciences Research
Co-authored papers 3
Co-authored papers 3
Stanford University.
Co-authored papers 3
Yale University
Co-authored papers 2
Cancer Center of Lyon
Co-authored papers 2
Dana-Farber Cancer Institute
Co-authored papers 2
Co-authored papers 2
PSL Research University, Institut Curie Research Center, INSERM U, Institut Curie
Co-authored papers 2
Co-authored papers 2
Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu
Co-authored papers 2
Co-authored papers 2
Co-authored papers 2
Broad Institute of MIT and Harvard
Co-authored papers 2
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Co-authored papers 2
Georgetown University Medical Center
Co-authored papers 2
Tohoku University Graduate School of Medicine
Co-authored papers 2